• Explore /
  • Poster
  • / A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015.

A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015.

Abstract Poster

Authors

null

Deirdre Jill Cohen

Icahn School of Medicine at Mount Sinai, New York, NY

Deirdre Jill Cohen , Josep Tabernero , Eric Van Cutsem , Yelena Y. Janjigian , Yung-Jue Bang , Shukui Qin , Zev A. Wainberg , Anran Wang , Natalyn Nicole Hawk , Chie-Schin Shih , Pooja Bhagia , Kohei Shitara

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04662710

DOI

10.1200/JCO.2022.40.4_suppl.TPS369

Abstract #

TPS369

Poster Bd #

M4

Abstract Disclosures

Similar Posters

First Author: Patricio Eduardo Yanez

First Author: Jong-Mu Sun

First Author: Jong-Mu Sun

First Author: Manish A. Shah